Closing the Loophole on "Home Brew" Tests
This article was originally published in RPM Report
Executive Summary
FDA's draft guidance on single-laboratory diagnostics may slow down the development of genomic testing in the short term. Over the long term, however, it will help validate the field and create a stronger foundation for personalized medicine.
You may also be interested in...
Reimbursing Designer Drugs
Now that FDA is pushing a regulatory pathway for personalized medicine through the Critical Path initiative, the next step for industry should be securing payment, especially given what could be relatively high price tags. So what are payors--and the biggest payor of all, CMS--doing to prepare? The answer is, not much.
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.